Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

Peter Leif Bergsagel, María Victoria Mateos, Norma C. Gutierrez, S Vincent Rajkumar, Jesús F. San Miguel

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a heterogeneous disease with certain genetic features [eg, t(4;14), del17p] associated with worse outcome. The introduction of thalidomide, lenalidomide, and bortezomib has dramatically improved the outlook for patients with MM, but their relative benefit (or harm) for different genetic patient subgroups remains unclear. Unfortunately, the small number of patients in each subgroup frequently limits the analysis of high-risk patients enrolled in clinical trials. Strategies that result in survival of high-risk genetic subgroups approximating that of patients lacking high-risk features are said to overcome the poor prognostic impact of these high-risk features. This outcome has been difficult to achieve, and studies in this regard have so far been limited by inadequate sample size. In contrast, strategies that compare the survival of high-risk genetic subgroups randomized to different treatment arms can identify approaches that improve survival. This type of analysis is clinically useful, even if the absolute gains do not improve outcomes to levels seen in patients without high-risk cytogenetics. Reviewing available data in high-risk MM from this perspective, it appears that bortezomib has frequently been associated with improved survival, whereas thalidomide maintenance has sometimes been associated with a shorter survival.

Original languageEnglish (US)
Pages (from-to)884-892
Number of pages9
JournalBlood
Volume121
Issue number6
DOIs
StatePublished - Feb 7 2013

Fingerprint

Multiple Myeloma
Survival
Thalidomide
Therapeutics
Cytogenetics
Sample Size
Maintenance
Clinical Trials

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. / Bergsagel, Peter Leif; Mateos, María Victoria; Gutierrez, Norma C.; Rajkumar, S Vincent; San Miguel, Jesús F.

In: Blood, Vol. 121, No. 6, 07.02.2013, p. 884-892.

Research output: Contribution to journalArticle

Bergsagel, Peter Leif ; Mateos, María Victoria ; Gutierrez, Norma C. ; Rajkumar, S Vincent ; San Miguel, Jesús F. / Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. In: Blood. 2013 ; Vol. 121, No. 6. pp. 884-892.
@article{7a66eff8182247a7b7511381b2d2478e,
title = "Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma",
abstract = "Multiple myeloma (MM) is a heterogeneous disease with certain genetic features [eg, t(4;14), del17p] associated with worse outcome. The introduction of thalidomide, lenalidomide, and bortezomib has dramatically improved the outlook for patients with MM, but their relative benefit (or harm) for different genetic patient subgroups remains unclear. Unfortunately, the small number of patients in each subgroup frequently limits the analysis of high-risk patients enrolled in clinical trials. Strategies that result in survival of high-risk genetic subgroups approximating that of patients lacking high-risk features are said to overcome the poor prognostic impact of these high-risk features. This outcome has been difficult to achieve, and studies in this regard have so far been limited by inadequate sample size. In contrast, strategies that compare the survival of high-risk genetic subgroups randomized to different treatment arms can identify approaches that improve survival. This type of analysis is clinically useful, even if the absolute gains do not improve outcomes to levels seen in patients without high-risk cytogenetics. Reviewing available data in high-risk MM from this perspective, it appears that bortezomib has frequently been associated with improved survival, whereas thalidomide maintenance has sometimes been associated with a shorter survival.",
author = "Bergsagel, {Peter Leif} and Mateos, {Mar{\'i}a Victoria} and Gutierrez, {Norma C.} and Rajkumar, {S Vincent} and {San Miguel}, {Jes{\'u}s F.}",
year = "2013",
month = "2",
day = "7",
doi = "10.1182/blood-2012-05-432203",
language = "English (US)",
volume = "121",
pages = "884--892",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

AU - Bergsagel, Peter Leif

AU - Mateos, María Victoria

AU - Gutierrez, Norma C.

AU - Rajkumar, S Vincent

AU - San Miguel, Jesús F.

PY - 2013/2/7

Y1 - 2013/2/7

N2 - Multiple myeloma (MM) is a heterogeneous disease with certain genetic features [eg, t(4;14), del17p] associated with worse outcome. The introduction of thalidomide, lenalidomide, and bortezomib has dramatically improved the outlook for patients with MM, but their relative benefit (or harm) for different genetic patient subgroups remains unclear. Unfortunately, the small number of patients in each subgroup frequently limits the analysis of high-risk patients enrolled in clinical trials. Strategies that result in survival of high-risk genetic subgroups approximating that of patients lacking high-risk features are said to overcome the poor prognostic impact of these high-risk features. This outcome has been difficult to achieve, and studies in this regard have so far been limited by inadequate sample size. In contrast, strategies that compare the survival of high-risk genetic subgroups randomized to different treatment arms can identify approaches that improve survival. This type of analysis is clinically useful, even if the absolute gains do not improve outcomes to levels seen in patients without high-risk cytogenetics. Reviewing available data in high-risk MM from this perspective, it appears that bortezomib has frequently been associated with improved survival, whereas thalidomide maintenance has sometimes been associated with a shorter survival.

AB - Multiple myeloma (MM) is a heterogeneous disease with certain genetic features [eg, t(4;14), del17p] associated with worse outcome. The introduction of thalidomide, lenalidomide, and bortezomib has dramatically improved the outlook for patients with MM, but their relative benefit (or harm) for different genetic patient subgroups remains unclear. Unfortunately, the small number of patients in each subgroup frequently limits the analysis of high-risk patients enrolled in clinical trials. Strategies that result in survival of high-risk genetic subgroups approximating that of patients lacking high-risk features are said to overcome the poor prognostic impact of these high-risk features. This outcome has been difficult to achieve, and studies in this regard have so far been limited by inadequate sample size. In contrast, strategies that compare the survival of high-risk genetic subgroups randomized to different treatment arms can identify approaches that improve survival. This type of analysis is clinically useful, even if the absolute gains do not improve outcomes to levels seen in patients without high-risk cytogenetics. Reviewing available data in high-risk MM from this perspective, it appears that bortezomib has frequently been associated with improved survival, whereas thalidomide maintenance has sometimes been associated with a shorter survival.

UR - http://www.scopus.com/inward/record.url?scp=84873595098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873595098&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-05-432203

DO - 10.1182/blood-2012-05-432203

M3 - Article

C2 - 23165477

AN - SCOPUS:84873595098

VL - 121

SP - 884

EP - 892

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -